[Edaily Reporter Kwon Oh Seok ] MedPacto, Inc.(235980)announced on the 18th that it has submitted an application to the U.S. Food and Drug Administration (FDA) for approval of an amendment to its Investigational New Drug (IND) application for a Phase 1/2 clinical trial of Bactosetip monotherapy in patients with recurrent, refractory, or progressive osteosarcoma.
Disclosure Plus
MedPacto, Inc. Submits Application to U.S. FDA for Approval of Amended Phase 1 and 2 Clinical Trial Protocol for Baektoxetip Monotherapy
Kwon Oh Seok
2026-09-18 18:07:35
Economy
Corporation
IT·Science
Economy
"1–2 Minutes Per Sample"... Technology That Assesses Camera Performance Without Prototypes [VC Cradle]
Every time the camera industry changes a single combination of lenses, sensors, and image processing, it creates samples, takes test shots, and then redesigns the system. As the number of combinations…
Corporation
“Is That Hideo?” JINYOUNG CO., LTD’s Heart-Fluttering ‘Boyfriend Look’ [Who’s Wearing It]
“Hideo-san” from the drama “100 Days of Lies” has traded his uniform for a cardigan. This is the outfit that JINYOUNG CO., LTD., a member of the group GOT7 and an actor, showcased on a YouTube channel…
IT·Science
“The Era of 1.5 Million Robots”… The Korean Company JP Morgan Has Singled Out
A forecast indicates that U.S. production of humanoid robots will reach up to 400,000 units by 2030 and 1.5 million units by 2035. Analysts predict that as the humanoid robot industry moves beyond tec…
